Syndax Pharmaceuticals (SNDX) Receivables - Net (2024 - 2026)

Syndax Pharmaceuticals' Receivables - Net history runs 3 years deep, the most recent figure standing at $38.1 million for Q1 2026.

• On a quarterly basis, Receivables - Net rose 142.44% year-over-year to $38.1 million in Q1 2026; TTM through Mar 2026 was $38.1 million, a 142.44% increase from a year earlier, with the FY2025 full-year figure at $38.0 million, up 399.82% from the prior year.
• Receivables - Net held at $38.1 million in Q1 2026 per SNDX's latest filing, from $38.0 million in the prior quarter.
• Across five years, Receivables - Net topped out at $38.1 million in Q1 2026 and bottomed at $7.6 million in Q4 2024.
• The 3-year median for Receivables - Net is $22.4 million (2025), against an average of $24.0 million.
• Across the five-year window, Receivables - Net surged 399.82% in 2025 and surged 142.44% in 2026, its largest moves.
• Year by year, Receivables - Net stood at $7.6 million in 2024, then jumped by 399.82% to $38.0 million in 2025, then rose by 0.32% to $38.1 million in 2026.
• Per Business Quant, the three latest SNDX Receivables - Net figures stand at $38.1 million (Q1 2026), $38.0 million (Q4 2025), and $25.4 million (Q3 2025).